Donanemab for Alzheimer Disease—Who Benefits and Who Is Harmed?-Reference-Cited by-同舟云学术

Donanemab for Alzheimer Disease—Who Benefits and Who Is Harmed?

Published:2023-08-08 Issue:6 Volume:330 Page:510
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Manly Jennifer J.¹,Deters Kacie D.²

Affiliation:

1. Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Department of Neurology, Columbia University Irving Medical Center, New York, New York

2. Department of Integrative Biology and Physiology, University of California, Los Angeles

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2807534/jama_manly_2023_ed_230053_1691423455.95026.pdf

Reference16 articles.

1. Estimating the prevalence of dementia and mild cognitive impairment in the US: the 2016 Health and Retirement Study Harmonized Cognitive Assessment Protocol Project.;Manly;JAMA Neurol,2022

2. The estimation of the global prevalence of dementia from 1990-2019 and forecasted prevalence through 2050: an analysis for the Global Burden of Disease (GBD) study 2019.;Nichols;Alzheimers Dement,2021

3. The structural and social determinants of Alzheimer’s disease related dementias.;Adkins-Jackson;Alzheimers Dement,2023

4. Plasma p-tau181, p-tau217, and other blood-based Alzheimer’s disease biomarkers in a multi-ethnic, community study.;Brickman;Alzheimers Dement,2021

5. Alzheimer’s disease biomarkers in Black and non-Hispanic White cohorts: a contextualized review of the evidence.;Gleason;Alzheimers Dement,2022

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates in Alzheimer's disease: from basic research to diagnosis and therapies;Translational Neurodegeneration;2024-09-04

2. Considering challenges for the new Alzheimer's drugs: Clinical, population, and health system perspectives;Alzheimer's & Dementia;2024-08-06

3. The utility of recruitment incentives in early Alzheimer's disease trials;Alzheimer's & Dementia;2024-07-27

4. Challenges for emergency departments: Anti‐amyloid therapy and amyloid‐related imaging abnormalities in persons with dementia;Journal of the American Geriatrics Society;2024-07-22

5. The path to next-generation disease-modifying immunomodulatory combination therapies in Alzheimer’s disease;Nature Aging;2024-06-05